Now part of PerkinElmer, Cisbio develops and markets products and technologies used for in vitro diagnostics and drug discovery. With the proprietary technology, HTRF®, the organization is a leader in homogeneous fluorescence detection methods, and offers first-class assays and services for drug discovery researchers. In addition, Cisbio Bioassays provides a broad range of immunoassays for in vitro diagnostics, mainly tailored for cancerous pathologies, as well as metabolic and auto-immune diseases. Based in Codolet, France, Cisbio owns facilities in Bedford, MA, U.S.A., in Chiba, Japan and Shanghai, China, and markets its offering globally.
1985
Cisbio raised undisclosed on July 1, 2016
Investors: Tikehau Capital